Halozyme Therapeutics, Inc. - HALO - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Halozyme Therapeutics, Inc. - SIC # 8731

Ticker	Exchange	SIC #	Website	Latest Ticker
HALO	Nasdaq	8731	http://www.halozyme.com	6.405 +0.185
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Halozyme Therapeutics, Inc. Halozyme Firing On All Cylinders - Should Investors Get Behind The Wheel? - Jun 17th, 2013 12:14 pm Halozyme Therapeutics Breaks Below 200-Day Moving Average - Notable for HALO - Jun 5th, 2013 2:49 pm Spectrum Pharma names Gustafson as new CFO - Jun 5th, 2013 8:50 am Spectrum Pharma names Gustafson as new CFO - Jun 5th, 2013 8:50 am Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer - Jun 3rd, 2013 5:52 am 3 Stocks to Watch Ahead of ASCO - May 28th, 2013 1:14 pm HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers - May 24th, 2013 7:24 am Ahead Of The Trend: 7 Rallying Stocks With Institutional Selling And Short Increases - May 23rd, 2013 12:25 pm CFO Moves: KeyCorp, Huntington Bancshares, Halozyme - May 23rd, 2013 10:28 am Halozyme names David Ramsay as CFO - May 23rd, 2013 10:25 am Halozyme names David Ramsay as CFO - May 23rd, 2013 10:25 am The Coming Diabetes Wars - May 23rd, 2013 9:48 am Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer - May 23rd, 2013 6:00 am American Society Of Clinical Oncology Abstracts Point To Potential Profits - May 21st, 2013 8:11 am Baxter Receives Marketing Authorization for HyQvia in European Union - May 21st, 2013 7:00 am 3 Humongous Health-Care Stocks This Week - May 18th, 2013 6:15 am HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh - May 17th, 2013 8:28 am Cancer Drug Drama Rocks 2 Biotech Stocks - May 16th, 2013 5:34 pm Halozyme rises on pancreatic cancer drug study - May 16th, 2013 2:41 pm Halozyme rises on prostate cancer drug study - May 16th, 2013 2:15 pm View All Current Headlines >>